Phase 0 1 trial
Phase 0
NCT03719105 Mar 2019 → Dec 2027 expected aggressive NK-cell leukemia New York Medical College
Recruiting
No outcome recorded
Phase 1 3 trials
Phase 1
NCT05581030 May 2023 → Oct 2026 expected acute lymphoblastic leukemia H. Lee Moffitt Cancer Center and Research Institute
Recruiting
No outcome recorded
Phase 1
NCT05034627 Aug 2022 → Dec 2025 overdue pancreatic adenocarcinoma OHSU Knight Cancer Institute
Active not recruiting
No outcome recorded
Phase 1
NCT04953780 Sep 2021 → Feb 2030 expected acute myeloid leukemia West Virginia University
Active not recruiting
No outcome recorded
Phase 2 2 trials
Phase 2
NCT06561074 Sep 2025 → Dec 2029 expected T-cell acute lymphoblastic leukemia , T-lymphoblastic lymphoma M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT02981628 Jun 2017 → Dec 2026 expected B-cell acute lymphoblastic leukemia Children's Oncology Group
Active not recruiting
No outcome recorded
Phase 2/3 1 trial
Phase 2/3
NCT04817761 Jul 2021 → Mar 2025 acute lymphoblastic leukemia Servier
Terminated
No outcome recorded
Stop: Business
Phase 3 2 trials
Phase 3
NCT03007147 Aug 2017 → Jun 2026 overdue B-cell acute lymphoblastic leukemia , T-cell acute lymphoblastic leukemia , mixed phenotype acute leukemia Children's Oncology Group
Active not recruiting
No outcome recorded
Phase 3
NCT00671034 Jul 2008 → Feb 2011 B-cell adult acute lymphocytic leukemia , B-cell childhood acute lymphoblastic leukemia Children's Oncology Group
Completed
No outcome recorded
Comparator or background therapy 15 trials
Phase 1
NCT05292664 Background Mar 2023 → Jul 2028 expected acute leukemia of ambiguous lineage , acute lymphoblastic leukemia , lymphoblastic lymphoma , myelodysplastic syndrome +1 Andrew E. Place, MD
Recruiting
No outcome recorded
Phase 1
NCT05326516 Background Mar 2022 → Jul 2024 acute lymphoblastic leukemia , acute undifferentiated leukemia , mixed phenotype acute leukemia Syndax Pharmaceuticals
Completed
No outcome recorded
Phase 1/2
NCT05192889 Background Aug 2022 → Jun 2024 overdue acute lymphoblastic leukemia St. Jude Children's Research Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT07636564 Background Oct 2026 → Apr 2031 expected B-cell acute lymphoblastic leukemia , T-cell acute lymphoblastic leukemia , acute leukemia of ambiguous lineage SWOG Cancer Research Network
Not yet recruiting
No outcome recorded
Phase 2
NCT06317662 Background Jun 2025 → Dec 2028 expected B-cell acute lymphoblastic leukemia , acute leukemia of ambiguous lineage National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 2
NCT06124157 Background May 2025 → Dec 2030 expected B-cell acute lymphoblastic leukemia National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 2
NCT06390319 Background Dec 2024 → Dec 2027 expected T-cell acute lymphoblastic leukemia , T-cell non-Hodgkin lymphoma , mixed phenotype acute leukemia St. Jude Children's Research Hospital
Recruiting
No outcome recorded
Phase 2
NCT06210750 Background Aug 2024 → Sep 2026 T-cell acute lymphoblastic leukemia , T-lymphoblastic lymphoma National Cancer Institute (NCI)
Withdrawn
No outcome recorded
Phase 2
NCT05761171 Background Jan 2024 → Dec 2027 expected acute lymphoblastic leukemia , mixed phenotype acute leukemia Children's Oncology Group
Active not recruiting
No outcome recorded
Phase 2
NCT04546399 Background Dec 2020 → Jun 2028 expected B-cell acute lymphoblastic leukemia , Down syndrome National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 2
NCT01574274 Comparator Jun 2012 → Jul 2021 overdue acute lymphoblastic leukemia , lymphoblastic lymphoma Dana-Farber Cancer Institute
Active not recruiting
No outcome recorded
Phase 2/3
NCT07072585 Background Aug 2026 → Sep 2035 expected T-cell acute lymphoblastic leukemia , T-lymphoblastic lymphoma Children's Oncology Group
Not yet recruiting
No outcome recorded
Phase 2/3
NCT03117751 Background Mar 2017 → Sep 2026 overdue lymphoblastic leukemia, acute, with lymphomatous features St. Jude Children's Research Hospital
Active not recruiting
No outcome recorded
Phase 3
NCT05602194 Background Aug 2023 → Sep 2026 overdue B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) , B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like , T-cell acute lymphoblastic leukemia , lymphoblastic lymphoma +1 Children's Oncology Group
Active not recruiting
No outcome recorded
Phase 3
NCT03959085 Background Oct 2019 → Mar 2032 expected B-cell acute lymphoblastic leukemia , central nervous system leukemia , lymphoblastic lymphoma , mixed phenotype acute leukemia +1 Children's Oncology Group
Recruiting
No outcome recorded
Show 10 more trials